Zura Bio’s (ZURA) “Neutral” Rating Reiterated at HC Wainwright

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 58.23% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Leerink Partners began coverage on Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target for the company. Piper Sandler reiterated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Finally, Chardan Capital reduced their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $15.80.

Zura Bio Price Performance

ZURA opened at $3.16 on Monday. The stock has a fifty day moving average of $4.20 and a 200-day moving average of $4.11. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, equities research analysts predict that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Insider Activity at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares of the company’s stock, valued at approximately $8,070,567.66. The trade was a 2.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zura Bio

Several hedge funds and other institutional investors have recently made changes to their positions in ZURA. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Zura Bio in the 3rd quarter valued at approximately $46,000. AQR Capital Management LLC bought a new position in shares of Zura Bio in the 2nd quarter valued at $43,000. SG Americas Securities LLC bought a new position in shares of Zura Bio in the 3rd quarter valued at $62,000. Renaissance Technologies LLC boosted its holdings in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after acquiring an additional 5,900 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Zura Bio during the 3rd quarter worth $71,000. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.